Silo Pharma and Resyca BV Collaborate on Innovative Nasal Spray Tech for PTSD Drug SPC-15

Silo pharma a biopharmaceutical firm in the developmental stage that specialises in creating innovative drug delivery and formulation strategies for both conventional medicines and psychedelic treatments, announced today that it has partnered with Resyca BV, a supplier of medical technology, on a Device and CMC Development Master Plan. The formulation-specific microchip-based spray technology selected by Silo for its lead candidate SPC-15, an intranasal preventive therapy for post-traumatic stress disorder (PTSD), is produced by Resyca, a joint venture between Bespak Group and Medspray Pharma BV.

According to Eric Weisblum, CEO of Silo Pharma, "the patented nasal spray system uses cutting-edge nose-to-brain drug dispersion, a delivery method that transports the molecules to the brain directly, bypassing the blood-brain barrier." We think that using this delivery strategy for SPC-15 might raise the drug's concentration in the brain.

The purpose of this Device and CMC Development Master Plan is to facilitate the large animal GLP (Good Laboratory Practice) research of SPC-15 that was previously disclosed and that is IND-enabling. It also aims to assist the development, clinical formulation, and stability of the study. Under the terms of an ongoing exclusive licence agreement, Silo is the exclusive owner of the spray mist technology developed by Medspray Pharma BV, one of Resyca BV's joint venture partners, for use with a variety of indications, including PTSD.

The U.S. Food and Drug Administration (FDA) received a pre-IND briefing package and meeting request from Silo, which is presently working on GLP-compliant pharmacokinetic and pharmacodynamic studies for SPC-15. The studies are the last actions needed to submit an IND application to the FDA in order to initiate the first in human